Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532073 | 1.00 | SRD5A1 (0.51) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL353895 | 0.90 | BAZ2B (0.56) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL13727452 | 0.90 | BAZ2B (0.52) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL7716113 | 0.88 | PTPRC (0.46) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL13548832 | 0.88 | MAPK14 (0.56) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL484748 | 0.87 | PBRM1 (0.51) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4179934 | 0.83 | SRD5A1 (0.55) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL8142034 | 0.81 | SRD5A1 (0.56) | SRD5A1SRD5A2ALDH1A1PTPRCMAPK14 | |
| SCHEMBL24357716 | 0.81 | KMT2A (0.53) | SRD5A1SRD5A2ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL8253223 | 0.81 | NPC1 (0.61) | SRD5A1SRD5A2CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368667-A1 | USP1 INHIBITOR | SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-4582427-A1 | USP1 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-26 | — | — | US | disclosed |
| CN-119497713-A | USP1 inhibitors | 上海齐鲁制药研究中心有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. | 2023-12-28 | — | — | US | disclosed |
| CN-116669736-A | Fused heterocyclyl-substituted cyclohexanediimide derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009120-A2 | HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS | IRM LLC (BM) | 2007-01-18 | — | — | WO | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-1996015099-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996015100-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | SRD5A1 258/4885SRD5A2 349/4885ALDH1A1 153/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | SRD5A1 1761/4885SRD5A2 2553/4885ALDH1A1 1842/4885 |
| US-20250368667-A1 | USP1 INHIBITOR | USP1, USP2, USP28 | SRD5A1 2077/4885SRD5A2 2811/4885ALDH1A1 644/4885 |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | SRD5A1 258/4885SRD5A2 349/4885ALDH1A1 153/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | SRD5A1 3050/4885SRD5A2 3954/4885ALDH1A1 3848/4885 |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | SRD5A1 258/4885SRD5A2 349/4885ALDH1A1 153/4885 |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | BRDT, BRPF3, BRIX1 | SRD5A1 3090/4885SRD5A2 2903/4885ALDH1A1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.